|Systematic (IUPAC) name|
|Legal status||Controlled (S8) (AU) Schedule I (US)|
|Mol. mass||303.35 g/mol|
|(what is this?)|
Hydromorphinol (RAM-320, 14-Hydroxydihydromorphine) is an opiate analogue that is a derivative of morphine, where the 14-position has been hydroxylated and the 7,8- double bond saturated. It has similar effects to morphine such as sedation, analgesia and respiratory depression, but is more potent and has a steeper dose-response curve and longer half-life. It is used in medicine as the bitartrate salt (free base conversion ratio 0.643, molecular weight 471.5) and hydrochloride (free base conversion ratio 0.770, molecular weight 393.9)
Hydromorphinol was developed in Austria in 1932. It is available, and commonly used, as a medicine in Sweden; in the United States, it was never available and is classified as a Schedule I drug with a DEA ACSCN of 9301. The 2013 DEA production quota for hydromorphinol is 54 grammes.
Hydromorphinol is metabolised mainly in the liver in the same fashion as many other opioids and is itself a minor active metabolite of 14-Hydroxydihydrocodeine, an uncommonly-used opiate (but is therefore also an active metabolite of a first-order active metabolite of oxycodone).
It is distributed under the trade name Numorphan in some countries, whereas this trade name is used for oxymorphone much more commonly. It is controlled under the Single Convention On Narcotic Drugs.
- US 2960505, Weiss U., published 11/15/1960
- Weiss, U.; Daum, S. J. (1965). "Derivatives of Morphine. Iv. 14-Hydroxymorphine and 14-Hydroxydihydromorphine". Journal of Medical Chemistry 8: 123–125. doi:10.1021/jm00325a028. PMID 14287245.
- Plummer, J. L.; Cmielewski, P. L.; Reynolds, G. D.; Gourlay, G. K.; Cherry, D. A. (1990). "Influence of polarity on dose-response relationships of intrathecal opioids in rats". Pain 40 (3): 339–347. doi:10.1016/0304-3959(90)91131-2. PMID 2326098.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|